Rallybio Corporation (RLYB)
Nasdaq · Healthcare · Biotechnology
$16.90−1.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $89.8M
- P/E (trailing)
- 2.1
- 52-week range
- $3.67 – $17.57
- 52-week change
- +281.25%
- EPS (trailing)
- $8.01
Fiscal year to Dec 2025
- Revenue
- $858K (+34.91%)
- Net income
- −$9.0M
- Operating margin
- −3853.6%
- Diluted EPS
- −$1.59
From the company’s annual report on SEC EDGAR.
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Headquarters: New Haven, United States · 7 employees · rallybio.com